The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on laparoscopic cystectomy.
It replaces the previous guidance on laparoscopic cystectomy (NICE interventional procedures guidance 26, December 2003).
This procedure is used to treat
- Invasive bladder carcinoma
- Ongoing incontinence due to paraplegia, where catheterisation results in infection and ongoing leakage
- Refractory complications in a defunctionalized bladder, where urinary diversion is already established
Laparoscopic cystectomy involves removing the bladder using small cuts (also known as 'keyhole surgery'). In women, the bladder is removed through the wall of the vagina. In men, the bladder is removed with the prostate gland, through a small cut in the wall of the abdomen. The tubes that carry urine from the kidneys to the bladder (the ureters) may then be connected to a bag worn outside the body, or parts of the bowel can be used to make an artificial bladder which is drained by a connection to the abdomen wall or to the tube that carries urine out of the body (the urethra).
This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account, and specifically any special arrangements relating to the introduction of new interventional procedures. The guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.
Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties. Providers should ensure that governance structures are in place to review, authorise and monitor the introduction of new devices and procedures.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.